Janssen Receives Positive CHMP Opinion for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
BEERSE, Belgium, 24 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for AKEEGA® (niraparib and AA), in the form of a DAT, given with P or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.[1]Niraparib is a highly selective poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.2 Together with AA, a cytochrome P450 17α-hydroxylase (CYP17) inhibitor,[1] the combination DAT regimen targets two oncogenic drivers (mutations responsible for both the development and maintenance of prostate cancer) in patients with mCRPC, namely androgen receptor axis (AR-axis) and BRCA1/2 gene mutations.[2],[3]Prostate cancer is the most common cancer in men in Europe.[4] Despite treatment advances, for those whose cancer has progressed to mCRPC, the impact can be devastating with an average overall survival ranging from 13-36 months.[5],[6],[7] Patients with mCRPC and BRCA gene mutations are more likely to have aggressive disease, poor outcomes and a shorter survival time.[8],[9],[10],[11] BRCA1/2 gene mutations have been identified in approximately 10-15 percent of patients with mCRPC.[12],[13]“Metastatic castration-resistant prostate cancer rem...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Abiraterone Acetate | Allergy & Immunology | Belgium Health | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemotherapy | Docetaxel | Epidemiology | Epithelial Cancer | European Medicines Agency (EMA) | Fallopian Tube Cancer | France Health | Gastric (Stomach) Cancer | Gastroschisis Repair | Genetics | Germany Health | Health Management | Heart | Hormones | Hospitals | Hypertension | Infectious Diseases | Italy Health | Japan Health | Learning | Legislation | Liver | Marketing | Neurology | Neuroscience | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Peritoneal Cancer | Pharmaceuticals | Prednisolone | Prednisone | Prostate Cancer | Pulmonary Hypertension | Science | Spain Health | Statistics | Study | Taxotere | UK Health | Universities & Medical Training | Urology & Nephrology | Vaccines